Relationship between asymmetric dimethylarginine and clinical, laboratory, ultrasonic parameters in patients with myocardial infarction after intravenous fibrinolysis

Main Article Content

V. I. Tseluyko
L. M. Yakovleva
O. E. Matuzok


The aim – to evaluate asymmetric dimethylarginine (ADMA) concentration and its possible relationship with clinical features, anamnesis, laboratory parameters, cardiac ultrasound in patients with ST-elevation myocardial infarction after intravenous fibrinolysis.
Material and methods. We examined 40 patients with myocardial infarction after intravenous fibrinolysis. Blood sampling was performed at admission. C-reactive protein (CRP) concentration was accessed. Quantitative determination of ADMA concentration was performed with high-performance liquid chromatography. Cardiac ultrasound was done in all patients. Fibrinolysis efficacy was evaluated according to the ECG criteria.
Results. ADMA concentration in examined patients was 0.1–4.94 mkmol/l. Patients were divided into four groups according to ADMA quartiles (increase of ADMA concentration from group I to group IV). All patients in group IV were smokers, the difference was significant in groups I and II (P=0.04). Time to fibrinolysis was significantly higher in group IV than in groups II (P=0.02) and III (P=0.04). Mean ADMA concentration was significantly higher in patients with anterior compared to patients with inferior infarction (1.79±1.5 and 0.8±0.75 mkmol/l, respectively, Р=0.02). In correlation analysis ADMA level was related to history of smoking, high-sensitive CRP and glycemia level at admission, time to fibrinolysis, heart rate on the second day of infarction, and ultrasonic parameters – end-diastolic volume (EDV), and-systolic volume and ejection fraction. Fibrinolysis was significantly less effective in patients with higher ADMA level.
Conclusion. Significant increase of ADMA level was found in presence of smoking, longer of time to fibrinolysis and in anterior localization of infarction. ADMA level increase was associated with increase of hsCRP level, younger age, EDV and admission glycemia increase, decrease of glomerular filtration rate and body mass index, increase of time to fibrinolysis (regression analysis). Fibrinolysis was significantly less effective in patients with higher ADMA level.

Article Details


myocardial infarction, asymmetric dimethylarginine, smoking, C-reactive protein, fibrinolysis efficacy


Пархоменко А.Н., Лутай Я.М., Иркин О.И и др. Клинико-прогностическое значение полиморфизма гена эндотелиальной NO-синтетазы у больных с острыми коронарными синдромами // Медицина неотложных состояний.– 2014.– № 3 (58).– С. 45–54.

Al Shammeri O., Garcia L.A. Thrombolysis in the age of primary percutaneous coronary intervention: mini-review and meta-analysis of early PCI // Intern. J. Health Sciences.– 2013.– Vol. 7, N 1.– P. 81–89.

Armstrong P.W., Gershlick A.H., Goldstein P. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction // New Engl. J. Medicine.– 2013.– Vol. 368, N 15.– P. 1379–1387. DOI: 10.1056/NEJMoa1301092

Badran M., Golbidi S., Ayas N. et al. Nitric oxide bioavailability in obstructive sleep apnea: interplay of asymmetric dimethylarginine and free radicals // Sleep disorders.– 2015.– article ID 387801.

Bae S.W., Stühlinger M.C., Yoo H.S. et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment // The Amer. J. Cardiology.– 2005.– Vol. 95, N 6.– P. 729–733.

Danchin N., Puymirat E., Steg P.G. et al. Five-year survival in patients with St-segment-elevation myocardial infarction ac­­cording to modalities of reperfusion therapy: the French Registry on Acute St-elevation and Non-ST-elevation Myocardial Infarction (fast-mi) 2005 Cohort // Circulation.– 2014.– Vol. 129, N 16.– P. 1629–1636. DOI: 10.1161/IRCULATIONAHA.113.005874

Feng W., Sun L., Song Y. et al. Relationship between C-reactive protein and the asymmetric dimethylarginine-induced endothelial dysfunction pathway in vasospastic angina // Pharmazie-An Intern. J. Pharm. Sciences.– 2014.– Vol. 69, N 3.– P. 234–237.

Gudjoncik A., Zeller M., Lorin J. et al. Dimethylarginines, blood glucose, and C-reactive protein in patients with acute myocardial infarction // Clin. Trials Regulatory Science in Cardiology.– 2016.– Vol. 16.– P. 6–11.

Koc F., Tokac M., Erdem S. et al. Serum asymmetric dimethylarginine levels in normotensive obese individuals // Med. Science Monitor.– 2010.– Vol. 16, N 11.– P. CR536–CR539.

Lai L., Ghebremariam Y.T. Modulating DDAH/NOS pathway to discover vasoprotective insulin sensitizers // J. Diabetes Research.– 2015.– Vol. 2016.– article ID 1982096.

Murphy R.B. et al. Inhibitors of the hydrolytic enzyme dimethylarginine dimethylaminohydrolase (DDAH): discovery, synthesis and development // Molecules.– 2016.– Т. 21, N 5.– P. 615. doi:10.3390/molecules21050615

Sen N., Ozlu M.F., Akgul E.O. et al. Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion // Atherosclerosis.– 2011.– Vol. 219, N 1.– P. 304–310.

Staab E.B., Weigel J., Xiao F. et al. Asymmetric dimethyl-arginine metabolism in a murine model of cigarette smoke-mediated lung inflammation // J. Immunotoxicology.– 2015.– Vol. 12 (3).– P. 273–282.

Steg P.G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) // Eur. Heart J.– 2012.– Vol. 33, N 20.– P. 2569–2619.

Stühlinger M.C., Conci E., Haubner B.J. et al. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury // Cardiovasc. research.– 2007.– Vol. 75.– N 2.– P. 417–425.

Sydow K., Fortmann S.P., Fair J.M. et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities // Clin. Chemistry.– 2010.– Vol. 56, N 1.– P. 111–120.

Szpak D., Grochowalski A., Chrząszcz R. et al. Tobacco smoke exposure and endothelial dysfunction in patients with advanced coronary artery disease // Pol. Arch. Med. Wewn.– 2013.– Vol. 123, N 9.– P. 474–481.

Tain Y.L., Hsu C.N. Toxic dimethylarginines: Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) // Toxins.– 2017.– Vol. 9, N 3.– 92. doi:10.3390/toxins9030092

Van de Werf F. The advantages of a pharmaco-invasive strategy // Rom. J. Cardiology.– 2016.– Vol. 26, N 1.– P. 6.

Zeller M., Korandji C., Guilland J.C. et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction // Arterioscler. Thromb. Vasc. Biology.– 2008.– Vol. 28, N 5.– P. 954–960.

Most read articles by the same author(s)

1 2 > >>